Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Allergen-Specific Immunotherapy by Recombinant Der P1 Allergen-Derived Peptide-Based Vaccine in an Allergic Mouse Model Publisher Pubmed



Asoudeh Moghanloo S1, 2 ; Forouzanfar M1 ; Jafarinia M1 ; Fazlollahi MR2 ; Kardar GA2, 3
Authors

Source: Immunity# Inflammation and Disease Published:2023


Abstract

Aim: Increased IgE levels have made house dust mite allergens one of the most frequent causes of allergies worldwide. Treatment reduces the IgE antibodies and types two cytokines, namely interleukin-4 (IL-4) and IL-13. Although existing treatments significantly reduce IgE or IL-4/IL-13, they are very costly. This study aimed to construct a recombinant protein derived from rDer p1 peptides in the form of an immunotherapy approach and to measure the response of IgE and IgG antibodies. Methods: The proteins were isolated, purified, and evaluated using the SDS-PAGE and Bradford test and confirmed by using Western blot. To evaluate immunotherapy efficiency, 24 BALB/C mice were sensitized intraperitoneally with house dust mites (HDM) adsorbed to Aluminum hydroxide (Alum) and randomly divided into four groups of six: control sensitized, HDM extract, rDer p1, and DpTTDp vaccine. To immunization, four groups of random mice were each treated with phosphate-buffered saline, 100 μg of rDer p1 protein, DpTTDp, or HDM extract, every 3 days. Direct ELISA determined HDM-specific IgG and IgE subclasses. Data were analyzed in SPSS and Graph pad prism software. Values of p <.05 were considered significant. Results: After immunization of mice, the rDer P1 and recombinant vaccine like HDM extract increased IgG antibody titer and decreased IgE-dependent reactivity in allergic mice to rDer P1. Also, the levels of inflammatory IL-4 and IL-13 cytokines as allergic stimulants decreased. Conclusion: The use of present available recombinant proteins is considered a viable, cost-effective, and long-term option for providing effective HDM allergy immunotherapy vaccines without side effects. © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Other Related Docs
10. Decorating and Loading Ghosts With Allergens for Allergen Immunotherapy, Human Vaccines and Immunotherapeutics (2017)
15. Efficacy and Safety of Omalizumab in Paediatric Age: An Update of Literature Data, Journal of Biological Regulators and Homeostatic Agents (2016)